MassBiologics and the Wadsworth Center teamed up to generate a panel of RBD-specific antibodies (“nanobodies” or VHHs) that can be used for identity tests in the manufacture of SARS-CoV-2 subunit vaccines.
MassBiologics used yeast-display technologies to identify nanobodies specific for each RBD VoC, while Wadsworth Center evaluated the nanobodies’ suitability to function in mock identity tests with drug substances and drug products.
MassBiologics and the Wadsworth Center developed critical reagents for use in developing analytical CMC assays involved in the manufacturing of SARS-CoV-2 subunit vaccines, which can help accelerate the manufacturing process.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
New York State Department of Health (Wadsworth Center)